electroCore (NASDAQ:ECOR) versus Critical Outcome Technologies (OTCMKTS:COTQF) Financial Survey

electroCore (NASDAQ:ECOR) and Critical Outcome Technologies (OTCMKTS:COTQF) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk and institutional ownership.

Valuation and Earnings

This table compares electroCore and Critical Outcome Technologies”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
electroCore	$32.03 million	1.62	-$13.97 million	($1.77)	-3.54
Critical Outcome Technologies	N/A	N/A	N/A	N/A	N/A

Critical Outcome Technologies has lower revenue, but higher earnings than electroCore.

Insider and Institutional Ownership

26.7% of electroCore shares are owned by institutional investors. 13.8% of electroCore shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares electroCore and Critical Outcome Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
electroCore	-44.08%	-1,956.38%	-83.30%
Critical Outcome Technologies	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current recommendations for electroCore and Critical Outcome Technologies, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
electroCore	1	1	1	0	2.00
Critical Outcome Technologies	0	0	0	0	0.00

electroCore currently has a consensus target price of $18.00, indicating a potential upside of 187.08%. Given electroCore’s stronger consensus rating and higher probable upside, analysts clearly believe electroCore is more favorable than Critical Outcome Technologies.

Summary

electroCore beats Critical Outcome Technologies on 6 of the 9 factors compared between the two stocks.

About electroCore

electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.

About Critical Outcome Technologies

Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company’s lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent’s University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.